COUR Pharmaceuticals closes its first institutional financing round in the Company's history led by Alpha Wave Ventures.

Today we announced that we have secured $105 million in Series A financing. This funding will support the advancement of our #MyastheniaGravis and #T1D programs into Phase 2 #ClinicalTrials. Read more here: brnw.ch/21wGvI6

In this STAT article by Allison DeAngelis, our CEO, John Puisis, discusses our Series A and the advancement of our nanoparticles in development to treat #autoimmune diseases. Read the article via the link in the post below.

Funds from our recently announced Series A will be used to support the advancement of our #MyastheniaGravis (MG) and #Type1Diabetes (#T1D) candidates into Phase 2a #ClinicalTrials. Read this BioPharma Dive article by Ben Fidler to learn more: brnw.ch/21wGAEj

#ICYMI, this Genetic Engineering & Biotechnology News article by Jonathan D. Grinstein, PhD covers the closure of our $105 million Series A and our nanoparticle approach to antigen-specific immune tolerance. Check it out here: brnw.ch/21wGGN7

Our Director of Immunology, Joseph Podojil, PhD, will be at the 7th ASIT Summit in Boston. He will lead a workshop on antigen selection and immune tolerance in #AutoimmuneDiseases. More here: brnw.ch/21wHNAp

If you’re attending the Myasthenia Gravis Foundation of America’s 2024 National Patient Conference in Tampa, don’t miss our booth! We look forward to discussing our #MyastheniaGravis research, including the #ClinicalTrial of our potential treatment, CNP-106. More info here: brnw.ch/21wJaFe

We’re excited to attend #IMMUNOLOGY24™ here in Chicago! Our Director of Immunology, Dr. Joe Podojil, will present data demonstrating the potential of our antigen-specific nanoparticle technology. Learn more about our presentation: brnw.ch/21wJoOc #AAI2024 #immunology

Join us in welcoming Paul Peloso, MD, as COUR’s CMO. His expertise in late-stage clinical development makes him a great addition to our team as we advance into Phase 2 studies of our potential treatments for #MyastheniaGravis & #Type1Diabetes. Read more: globenewswire.com/en/news-releas…

Over 70,000 in the U.S. are diagnosed with #MyastheniaGravis with no cure available. During #MGAwarenessMonth, we stand with MG patients as we advance our #ClinicalTrial of CNP-106, developing a new treatment for a better tomorrow. Learn more: bit.ly/4c2AgLP #MGStrong

In this Drug Target Review article, our CEO, John Puisis, discusses our versatile #nanoparticle platform and its potential to treat #AutoimmuneDiseases like #MyastheniaGravis & #Type1Diabetes. Read more here: bit.ly/3ySKjok

Today, Tim Walbert was appointed to our Board of Directors. We are excited to leverage his experience leading companies through discovering, developing & commercializing novel treatments for underserved patient populations. Read more in our press release: bit.ly/45IAkOJ

After raising $105 million in our Series A earlier this year, we're thrilled that as part of Chicago Inno’s Fire Awards, we've been recognized as one of 50 companies setting Chicago’s innovation economy ablaze. Check out the full list by Alex Zorn here: bit.ly/3VMASPn

In the latest episode of The Bio Report with @DSLevine, our CEO, John Puisis, and VP of Immunology & Innovation, Adam Elhofy, discuss our development of nanoparticles that elicit antigen-specific tolerance without immunosuppression. Listen here: bit.ly/3LLD4Sk

Today we shared that John J. Puisis will transition his role as President & CEO of COUR to current COO, Dannielle Appelhans. With her exceptional performance and her notable industry experience, we are confident she will lead COUR to new growth. Read more: bit.ly/4c6yPLX

We’re proud to share that COUR has been named to the 2024 #Fierce15 by FierceBiotech! This award celebrates the most innovative and forward-thinking companies in biotechnology. See the full list to learn more about our recognition: bit.ly/3yyOvd6

🎤 On August 20, join our CMO, Paul Peloso, M.D., as he highlights our #nanoparticle technology and discusses our ongoing #ClinicalTrial in #MyastheniaGravis during a webinar hosted by Myasthenia Gravis Foundation of America. Register to watch here: bit.ly/4ciYmSo

Next week our Director of Immunology, Joseph Podojil, Ph.D., will present at EFIS’s 7th European Congress of Immunology in Dublin. Learn about his presentation here: eci2024.org/programme/ #ECI2024

We are excited to interact with the #MGCommunity at the upcoming Community Health Fair hosted by Myasthenia Gravis Foundation of America on September 14 in Chicago. Stop by our booth to meet our team and learn about the ongoing #ClinicalTrial evaluating our potential treatment for #MyastheniaGravis.

Our President & CEO, Dannielle Appelhans, and CMO, Dr. Paul Peloso, will present at Stifel’s Immunology & Inflammation Virtual Summit on 9/18 at 3:00 p.m. ET. Tune in to hear about our portfolio of #nanoparticle treatments for #autoimmune diseases: bit.ly/3Typ1DY